Kevin Tang has served as a member of our board of directors since February 2009 and as chairman since July 2012 Mr. Tang is the Managing Director of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Tang Capital Management holds a significant ownership position in A.P. Pharma's common stock. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex. Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm's Life Sciences research group. He currently serves as a director of Ardea Biosciences, Inc. and Penwest Pharmaceuticals, as well as two private companies, RadPharm, Inc., and Prospect Therapeutics, Inc. Mr. Tang received a BS degree from Duke University.
Barry D. Quart, Pharm.D. joined A.P. Pharma in May 2013 as Chief Executive Officer and has served as a member of our board of directors since June 2012. Dr. Quart was most recently President and Chief Executive Officer of Ardea Biosciences, Inc., a biopharmaceutical company, since its founding in December 2006. Ardea was acquired by AstraZeneca PLC for $1.26 billion in June 2012. Previously, he was with Pfizer as Senior Vice President, Pfizer Global Research and Development and the director of Pfizer's La Jolla Laboratories, where he was responsible for approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Agouron was acquired by Warner-Lambert for $2.1 billion in 1999. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept, which went from the lab bench to new drug application approval in 38 months. Dr. Quart received his Pharm.D. degree from University of California, San Francisco.
Robert Rosen joined A.P. Pharma as Senior Vice President and Chief Commercial Officer in October 2012 and was appointed to President in May 2013. Mr. Rosen has also served as a member of our board of directors since July 2012. Prior to joining A.P, Pharma, he served as global head of oncology at Bayer HealthCare, where he was responsible for the development of the global oncology business unit for regions that included the Americas, Europe, Japan, and Asia Pacific from 2005 to 2011. During his tenure at Bayer Healthcare, he led the launch of Nexavar for the treatment of renal cell carcinoma and hepatocellular carcinoma. Nexavar's worldwide sales in 2011 were $1.0 billion. He also led premarket activities for Stivarga for gastrointestinal stromal tumors and colon cancer and alpharadin for prostate cancer. From 2002 to 2005, Mr. Rosen was vice president of the oncology business unit at Sanofi-Synthèlabo, where he was responsible for the development of Sanofi's U.S. oncology business and the launch of Eloxatin for colon cancer. Eloxatin U.S. sales in 2005, its third full year on the market, were $1.1 billion, ranking it among the industry's most successful oncology drug launches. Mr. Rosen received a Bachelor of Science degree in Pharmacy from Northeastern University.
Stephen R. Davis joined A.P. Pharma as Executive Vice President and Chief Operating Officer in May 2013 and has served as a member of our board of directors since June 2012. Mr. Davis was most recently Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc. He has completed numerous strategic transactions between biotechnology and pharmaceutical companies, including the recent $1.26 billion acquisition of Ardea by AstraZeneca PLC. Prior to Ardea, Mr. Davis served as President and Chief Executive Officer of Neurogen Corporation, a biopharmaceutical company acquired by Ligand Pharmaceuticals. Before becoming Neurogen's Chief Executive Officer, Mr. Davis served in numerous executive roles at Neurogen completing multiple collaboration and asset acquisition and sale transactions with global pharmaceutical companies. Previously, Mr. Davis practiced as a corporate and securities attorney with a Wall Street law firm and as a Certified Public Accountant with a major accounting firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.
Mark S. Gelder, M.D. joined A.P. Pharma as Senior Vice President and Chief Medical Officer in December 2012. Dr. Gelder, most recently, was the vice president and global head of medical affairs and pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare, Dr. Gelder was the vice president, global medical affairs oncology for Bayer Healthcare Pharmaceuticals, and was responsible for the global medical strategy supporting the launch of Nexavar®, Stivarga®, and Alpharadin® global launch programs. Dr. Gelder was also the global therapeutic area director of oncology at Wyeth, with a focus on the commercial launch of Torisel®. Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, working on Sutent®, and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received a bachelor's of science degree from Colgate University, and his doctor of medicine from the University of Virginia's School of Medicine.
Jesse Hollingsworth joined A.P. Pharma as Vice President of Sales in February 2013. Most recently, Mr. Hollingsworth served as the Senior Director of Group Purchasing Organizations (GPO) and Trade Strategy at Dendreon where he developed and implemented the company's national GPO strategy. During this time, he was also responsible for building and managing relationships with top community oncologists for the company. Prior to his work at Dendreon, Mr. Hollingsworth was the Senior Director of Strategic Business Development and Marketing at ION Solutions, an Amerisource Bergen Specialty Group where he focused on GPO, payer and practice solutions. Earlier, he worked at Amgen, Inc., where, as the Marketing Director for the oncology business unit, Mr. Hollingsworth was responsible for US reimbursement and access programs for the Neulasta®, Neupogen® and Vectibix® franchises. Mr. Hollingsworth received a Bachelor of Science degree in Journalism and Communications from the University of Florida and a Master of Health Administration from the University of South Florida.
Daniel Martin joined A.P. Pharma as Vice President of Marketing in December 2012. Mr. Martin brings 14 years of diverse health care industry experience and nearly nine years of oncology marketing experience to A.P. Pharma. Most recently he was the head of US marketing at Dendreon, reporting to the executive vice president and chief commercial officer. Prior to joining Dendreon, Mr. Martin spent 7 years in positions of increasing responsibility within Amgen's Oncology Business Unit. Mr. Martin worked on Amgen's Aranesp® and Neulasta® franchises and then led the launch of XGEVA® into both oncology and urology. Prior to these roles, Mr. Martin led strategic planning and operations for Amgen's oncology GPO team. Prior to Amgen, Mr. Martin worked as a management consultant with Deloitte Consulting where he specialized in pharmaceutical marketing and commercial operations. Mr. Martin holds a bachelor's of arts in economics and biology from the University of Virginia and received his master's in business administration from the University of Pennsylvania's Wharton School of Business.
Thomas Ottoboni, Ph.D. joined A.P. Pharma as Vice President of Pharmaceutical Development in March 2012. Prior to joining us, Dr. Ottoboni was Vice President of Research and Development at Talima Therapeutics, where he worked on the development of a drug delivery implant to treat onychomycosis. Dr. Ottoboni has also served as Executive Vice President of Strategy and Operations at Point Biomedical, where he developed several imaging and drug delivery systems. Previously, Dr. Ottoboni served as Manager of Systems Development and Drug Delivery Research for InSite Vision, where he developed ophthalmic pharmaceutical delivery systems and also served as Director of Drug Delivery at Vitaphore. Dr. Ottoboni is an inventor on more than 19 US patents in organic and macromolecular chemistry and received a B.S. degree in Chemistry as well as a Ph.D. in Organic Chemistry from the University of California, Berkeley.
Thomas Pitler, Ph.D. joined A.P. Pharma as Vice President of Business Development in September 2012. Most recently, Dr. Pitler was vice president of business development at Chimerix, where he was responsible for the company's interactions with potential partners, leading the due diligence and negotiations process around the licensing of clinical stage programs, preclinical assets and underlying technology. Earlier, Dr. Pitler held the position of senior vice president, chief business and financial officer at Neurogen, Inc. (acquired by Ligand Pharmaceuticals). At Neurogen, Dr. Pitler established research and development collaborations with pharmaceuticals companies, including Merck and Aventis. Dr. Pitler was also a Research Assistant Professor at the University of Maryland School of Medicine and has held other academic positions. He received a B.A. in Biology and a Ph.D. in Physiology from Wake Forest University.
Joel Schaedler joined A.P. Pharma as Vice President of Market Access in December 2012. Mr. Schaedler brings over 17 years of specialty pharmaceutical and healthcare distributor experience to A.P. Pharma. Most recently, he was the senior vice president of business development at P4 Healthcare, which was acquired by Cardinal Health in 2010. Prior to his tenure at Cardinal Health, Mr. Schaedler was the regional vice president of sales for Bionicare Medical Technologies where he focused on the development of marketing strategies, physician targeting and creation of operational efficiencies. He has also held positions of increasing responsibilities with Amerisource Bergen Specialty, Centocor (acquired by Johnson & Johnson) and Sanofi-Aventis. Mr. Schaedler has a bachelor's of arts degree in business administration from Kent State University in Kent, Ohio.
A.P. Pharma's pivotal Phase 3 clinical trial, initiated in May 2006, was a multicenter, randomized, observer-blind, actively-controlled, double-dummy, parallel group study that compared the efficacy of APF530 with palonosetron. The trial stratified patients into two groups, one receiving moderately and the other receiving highly emetogenic chemotherapeutic agents in accordance with the Hesketh algorithm, which assigns emetogenic levels based on the chemotherapy agent, drug dosage and combinations employed. In each group, the patients were randomized to receive in the first chemotherapy treatment cycle either APF530 high dose (10 mg granisetron), APF530 low dose (5 mg granisetron) or the currently approved dose of palonosetron. In subsequent treatment cycles (up to three additional cycles), patients who received palonosetron were re-randomized to either of the two APF530 doses.
During 2006 and the first half of 2007, all patient enrollments were within the U.S. Beginning in the second half of 2007, enrollments were broadened to include sites in India and Poland. A.P. Pharma's pivotal Phase 3 study, comparing the efficacy of APF530 with palonosetron, completed patient enrollment of 1,395 patients in June 2008, and the Company announced top-line results on September 30, 2008.
The goals of the trial were to demonstrate the safety and efficacy of APF530 in the treatment of CINV following the administration of highly or moderately emetogenic chemotherapy, and to establish an effective dose for APF530. In the trial, 5 mg and 10 mg doses of granisetron were evaluated, and based on the results, the 10 mg dose appears to provide greater efficacy with a side effect profile similar to the 5 mg dose. As such, the APF530 10 mg dose is the proposed therapeutic dose included in the NDA. The NDA was submitted under section 505(b)(2) of the FDCA, whereby A.P. Pharma can rely on the significant clinical data for safety and efficacy of APF530's active ingredient, granisetron.
The trial was structured to compare the two APF530 doses with palonosetron in four different primary efficacy endpoints, non-inferiority to palonosetron for the prevention of acute and delayed CINV in patients receiving moderately emetogenic chemotherapies, and non-inferiority and superiority to palonosetron for the prevention of acute and delayed CINV, respectively, in patients receiving highly emetogenic chemotherapies. Palonosetron is not FDA approved for the prevention of delayed-onset CINV in patients receiving highly emetogenic chemotherapies; therefore, APF530 needed to be deemed superior to palonosetron for this endpoint to obtain a corresponding label claim. The 10 mg dose of APF530 achieved complete response (CR) rates that were numerically higher than palonosetron across all four assessments. These results achieved non-inferiority to palonosetron for all four assessments, but did not achieve the superiority endpoint for the highly emetogenic delayed-onset assessment. CR was defined as the absence of emetic episodes or use of antiemetic rescue medications during a specified period of time. The time periods studied for CINV onset were acute (0 to 24 hours after chemotherapy) and delayed (24 to 120 hours after chemotherapy).
APF530 was generally well tolerated, with a side effect profile consistent with previous human use of granisetron and only one serious adverse event reported as possibly attributed to APF530.
Post-hoc analysis of Phase 3 data by chemotherapy regimen showed good response rates for different regimens.
The Phase 3 trial protocol predefined multiple primary and secondary endpoints, including complete response, complete control (no emesis, no rescue therapy and no-greater-than-mild nausea) and total response (no emesis, no rescue therapy and no nausea) measured over defined time intervals (acute, delayed and overall). Although there were no significant differences between the APF530 10 mg dose vs. palonosetron, the response rates for APF530 10 mg dose were higher than palonosetron in all nine analyses for moderately emetogenic chemotherapy and in five of nine analyses for highly emetogenic chemotherapy.
Investigators were required to observe and record all reactions associated with the subcutaneous injection site on days one and five for each treatment cycle. Overall, greater than 90% of the recorded observations were mild in severity, the most common being redness and bruising. With each additional cycle of treatment with APF530, the frequency of injection site reactions decreased, indicating APF530 can be administered for multiple cycles.
During the trial, patients received more than 1,600 separate injections of APF530 10 mg dose. Assessment of any injection site pain was made on days one and five of treatment: on day one, less than 0.1% of injections produced any reports of pain; on day five approximately 4% of injections produced reported pain. All but four of these reports of pain were recorded as mild, with the four recorded as moderate.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 2, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that its Board of Directors has appointed a new management team to lead the Company. Effective today, Barry D. Quart, Pharm.D. will join the Company as Chief Executive Officer, Robert Rosen, who joined A.P. Pharma in October 2012 as Senior Vice President and Chief Commercial Officer, will be promoted to the role of President, and Steve Davis will join the Company as Executive Vice President and Chief Operating Officer. Each executive joined A.P. Pharma's Board of Directors in 2012 and will continue to serve as directors.
"We are very excited to assemble a team with such extensive industry experience and impressive track records to maximize the value of A.P. Pharma's lead drug candidate, APF530, and capitalize on the Company's BiochronomerTM drug delivery platform," said Kevin C. Tang, Chairman of the A.P. Pharma Board of Directors. "Barry was instrumental in building two biopharmaceutical companies, Ardea Biosciences and Agouron Pharmaceuticals, that were acquired by major pharmaceutical companies for more than $1 billion each. Rob brings deep experience in the commercialization of oncology drugs and was responsible for the launch of two products, Nexavar and Eloxatin, that each achieved sales of more than $1 billion only a few years following market introduction. Steve most recently was the chief architect in the transaction resulting in the sale of Ardea Biosciences to AstraZeneca for more than $1 billion."
"I would also like to extend my thanks to John Whelan and Michael Adam, Ph.D., each of whom made valuable contributions to A.P. Pharma and will be stepping down from their current positions," continued Mr. Tang.
"I am very excited to join A.P. Pharma and to work with the stellar management team the Company has assembled. APF530 and the Biochronomer drug delivery technology, which has the potential to be used for a broad range of drugs, provide a solid platform for building a successful company," said Dr. Quart.
Dr. Quart was most recently President and Chief Executive Officer of Ardea Biosciences, Inc., a biopharmaceutical company, since its founding in December 2006. Ardea was acquired by AstraZeneca PLC for $1.26 billion in June 2012. Previously, he was with Pfizer as Senior Vice President, Pfizer Global Research and Development and the director of Pfizer's La Jolla Laboratories, where he was responsible for approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Agouron was acquired by Warner-Lambert for $2.1 billion in 1999. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept, which went from the lab bench to new drug application approval in 38 months. Dr. Quart received his Pharm.D. degree from University of California, San Francisco.
Prior to joining A.P. Pharma as Senior Vice President and Chief Commercial Officer, Mr. Rosen served as global head of oncology at Bayer HealthCare, where he was responsible for the development of the global oncology business unit for regions that included the Americas, Europe, Japan, and Asia Pacific from 2005 to 2011. During his tenure at Bayer Healthcare, he led the launch of Nexavar for the treatment of renal cell carcinoma and hepatocellular carcinoma. Nexavar's worldwide sales in 2011 were $1.0 billion. He also led premarket activities for Stivarga for gastrointestinal stromal tumors and colon cancer and alpharadin for prostate cancer. From 2002 to 2005, Mr. Rosen was vice president of the oncology business unit at Sanofi-Synthèlabo, where he was responsible for the development of Sanofi's U.S. oncology business and the launch of Eloxatin for colon cancer. Eloxatin U.S. sales in 2005, its third full year on the market, were $1.1 billion, ranking it among the industry's most successful oncology drug launches. Mr. Rosen received a Bachelor of Science degree in Pharmacy from Northeastern University.
Mr. Davis was most recently Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc. He has completed numerous strategic transactions between biotechnology and pharmaceutical companies, including the recent $1.26 billion acquisition of Ardea by AstraZeneca PLC. Prior to Ardea, Mr. Davis served as President and Chief Executive Officer of Neurogen Corporation, a biopharmaceutical company acquired by Ligand Pharmaceuticals. Before becoming Neurogen's Chief Executive Officer, Mr. Davis served in numerous executive roles at Neurogen completing multiple collaboration and asset acquisition and sale transactions with global pharmaceutical companies. Previously, Mr. Davis practiced as a corporate and securities attorney with a Wall Street law firm and as a Certified Public Accountant with a major accounting firm. Mr. Davis received his B.S. in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.
A.P. Pharma, Inc. (OTCBB:APPA.OB) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. The U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of the New Drug Application (NDA) for APF530, and has set a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2013.
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). The CRL describes the following issues that must be addressed.
With respect to chemistry, manufacturing and controls (CMC), the FDA has requested the refinement of one product quality analytical test method, and that certain deficiencies identified during facility pre-approval inspections be addressed.
The FDA has requested that a human factors validation study evaluating the usability of the APF530 syringe system together with its proposed product labeling and instructions for use be conducted with product assembled using a validated, commercial process.
With respect to clinical, the FDA has requested a re-analysis of the existing Phase 3 clinical data that reclassifies patients into those receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC) according to the recently modified ASCO 2011 Guideline. The FDA did not request any new clinical studies.
"We appreciate the FDA's thorough review of the APF530 NDA," stated John B. Whelan, A.P. Pharma's president and chief executive officer . "While disappointed in today's notification, we believe that the issues raised in the CRL are addressable, and we remain firmly committed to the successful development of APF530, which we believe will fulfill an important unmet need and improve the lives of patients suffering from CINV. In order to allow us time to carefully address the issues raised in the CRL, we are now projecting product launch for the first half of 2014, versus our prior guidance of the second half of 2013."
A.P. Pharma will host a conference call on Thursday, March 28, 2013 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Interested investors may participate in the conference call by dialing (877) 856-1964 (domestic) or (719) 386-0001 (international) and use participant code 135738. In addition, the live conference call is being webcast and can be accessed on the "Calendar of Events" page of the "Investors" section of the Company's website at www.appharma.com. A replay of the webcast will be posted to this same section of the website available approximately two hours after the call.
A.P. Pharma's lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company's proprietary Biochronomer™ drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy.
A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. A.P. Pharma resubmitted its New Drug Application (NDA) for APF530 to the U.S. Food and Drug Administration (FDA) in September 2012 and received a Complete Response Letter in March 2013. For further information, please visit the Company's web site at www.appharma.com.


Experts agree that the recession exposes all types of businesses, including medical practices, to a greater risk of employee fraud and embezzlement. There are many cases of employee embezzlement that can remain undetected for long periods of time, costing practices thousands of dollars from their top and bottom lines. In this article, we explore the reasons employees embezzle, the areas in which medical practices are at risk, and ways to safeguard your practice from this threat—in good times and in bad.


Discovery Bay Hotel Limited ("the Company") is committed to protecting your privacy.
When you visit our website at www.aubergediscoverybay.com, the website may place "cookie" in your computer's browser to collect your personal identification data such as name, HKID card number / passport number, email address, address, telephone number, credit card number and other relevant information to realize your preferences. Failure to supply such data may result in the Company's being unable to provide its services to you.
The purposes for which we may use the data collected or to be collected by the Company are divided into obligatory purposes and voluntary purposes. If the data is to be used for an obligatory purpose, you MUST provide the data to the Company if you want the Company to provide the services for which you are applying. If the data is only to be used for a voluntary purpose, the Company will obtain your consent and you can tell the Company not to use the data for that purpose and we will not do so.
conducting customer and service surveys.
We intend to use your personal data including your name, address, telephone numbers, email and other contact information collected for marketing communications such as direct-mail, email, telephone calls and SMS containing news, promotions, offers, events to be offered by us or by our business partners or future marketing purposes and/or joint promotion with our subsidiaries, holding companies, associated companies, affiliates or in conjunction with products/services offered by our affiliates or business partners in relation to the following classes of products and services: accommodation, travel, transportation, retail, food and beverage, credit cards, financial and investment services, wedding and banquet, conference and event, real estate, entertainment, publications, fashion and jewellery, leisure and sports, health and wellness, spa and body care, telecommunications, social networking, media and public relations.
We may not use your personal information for direct marketing without your consent. If you do not allow and agree us to use the data for the voluntary purposes including direct marketing as listed above, please tick the opt-out checkbox when you fill in an online form on the booking engine and any other documents (if applicable).
You will be removed from our mailing list within SEVEN days upon our receipt of your request.
You may also request the Company to delete the data from any active mailing or distribution list. To exercise any of your rights, contact us at the address or email the Company marking your communication "Confidential".


text:
Q: How do I get embedded Excel files to open inside Internet Explorer? Here's my problem: I have a web application that needs to open Excel files embedded into the web page. However, Internet Explorer (9 in this case, but the same goes for 8) only gives me the option to save or open the file and when I choose open, the file is opened within a new Excel window.
As far as I understand, opening files within IE should be the default behaviour, but for some reason that seems to have been altered in my installation and I can't seem to find a way to fix that. I'm running Windows 7, so there's no File Types tab under Folder Options in Windows Explorer.
Any ideas on how to fix this?

A: Opening Excel spreadsheets in IE doesn't get you the same functionality and menu structure as in Excel, but is possible.
Getting this to work requires registry hacks. If you intend to go this way, better create first a system restore point just in case.
The registry hack is described briefly for Office 2007 in :
Opening Office Documents (Word, Excel) in TWebBrowser on Vista and Office 2007
Which includes these registry changes :
[HKEY_LOCAL_MACHINE\SOFTWARE\Classes\Excel.Sheet.8]
"BrowserFlags"=dword:80000A00
[HKEY_LOCAL_MACHINE\SOFTWARE\Classes\Excel.Sheet.12]
"BrowserFlags"=dword:80000A00

For Office 2010, the keys and values are slightly modified.
You may find some more detail about these keys and values in this old Microsoft article :
How to configure Internet Explorer to open Office documents in the appropriate Office program instead of in Internet Explorer
although it is oriented in the opposite direction.

redpajama_set_name: RedPajamaStackExchange


text:
Graph the solution set of systems of two linear inequalities in two variables on the coordinate plane
Popular Tutorials in Graph the solution set of systems of two linear inequalities in two variables on the coordinate plane
How Do You Solve an OR Compound Inequality and Graph It On a Number Line?
Trying to solve a compound inequality? No problem! This tutorial will take you through the process of splitting the compound inequality into two inequalities. Then you'll see how to solve those inequalities, write the answer in set builder notation, and graph the solution on a number line.
How Do You Solve a System of Inequalities by Graphing?
There are many different ways to solve a system of inequalities. In this tutorial, you'll see how to solve such a system by graphing both inequalities and finding their intersection. Check it out!
How Do You Solve an AND Compound Inequality and Graph It On a Number Line?
Trying to solve a compound inequality? No sweat! This tutorial will take you through the process of solving the inequality. Then you'll see how to write the answer in set builder notation and graph it on a number line. You'll see it all in this tutorial!
Other topics in Linear functions, equations, and inequalities. The student applies the mathematical process standards when using graphs of linear functions, key features, and related transformations to represent in multiple ways and solve, with and without technology, equations, inequalities, and systems of equations.:
Determine the slope of a line given a table of values, a graph, two points on the line, and an equation written in various forms, including y = mx + b, ax + by = c, and y - y1 = m(x - x1)
Graph linear functions on the coordinate plane and identify key features, including x-intercept, y-intercept, zeros, and slope, in mathematical and real-world problems
Calculate the rate of change of a linear function represented tabularly, graphically, or algebraically in context of mathematical and real-world problems
Graph the solution set of linear inequalities in two variables on the coordinate plane
Estimate graphically the solutions to systems of two linear equations with two variables in real-world problems
Graph systems of two linear equations in two variables on the coordinate plane and determine the solutions if they exist

redpajama_set_name: RedPajamaCommonCrawl


text:
Archive for the 'first look' Category
Posted: November 13, 2018 by Amit Sharma in cinema, film, first look, Trailer
Tags: Danis Tanovic, digital premiere, Emraan Hashmi, first look, trailer, zee5
Danis Tanovic's controversial film Tigers is getting a worldwide digital release on ZEE5 on 21st of this month.
The trailer of the film was dropped some time back. Do take a look.
Directed By: Danis Tanovic
Produced By: Prashita Chaudhary, Kshitij Chaudhary, Guneet Monga, Anurag Kashyap, Andy Paterson, Cat Villers, Cedomir Kolar and Marc Baschet
Cast: Emraan Hashmi, Geetanjali, Adil Hussain & Danny Huston
Sceenplay: Danis Tanovic & Andy Paterson
Music: JAM8
DOP: Erol Zubcevic
Editor: Prerna Saigal
Sound Designer: Anthony B Jayaruban
Production designer: Rachna Rastogi & K.K. Muralidharan
Costume Designer: Niharika Bhasin khan
Casting: Seher Latif, CSA
Line Producer: Vishal Bajaj
Posted: November 7, 2018 by Amit Sharma in film, first look
Tags: Adil Hussain, Danis Tanovic, Emraan Hashmi, Sikhya Entertainment, Supriya Pathak, world digital premiere, zee5
Come November 21st, and fans of Danis Tanovic can watch his much awaited and controversial film Tigers, on Zee's online streaming platform ZEE5.
The film, based on a real life story, stars Emraan Hashmi, where he plays a Pakistani salesman Syed Aamir Raza, who is fighting a company (allegedly Nestle) whose baby formula is killing infants. The starcast of the film includes Adil Hussain, Supriya Pathak, Danny Huston and Satyadeep Mishra. Allegedly, Nestle paid the makers of the film not to release the film in theatres.
It's produced by Guneet Monga's Sikhya Entertainment, and is ZEE5's first original Hindi film. It premiered at TIFF 2015.
Tanovic has directed films like Death in Sarajevo, Hell, Triage, and No Man's Land – which won him an Academy Award in 2002.
First Look: Tumbbad Trailer
Posted: September 25, 2018 by Amit Sharma in cinema, first look
Tags: Aanand L. Rai, Anand Gandhi, Eros, mythological, Sohum Shah, Thriller, trailer, Tumbbad, Venice Biennale, Venice International Film Festival
We have written in the past about the excitement around our home-grown mythological thriller Tumbbad at Venice Film Festival.
The trailer for the film was released today. Take a look.
The trailer showcases the mood, the mystery, and the special effects that are woven into this story of a goddess who created the entire universe, and the horrors around it. As we write this, the trailer has generated a lot of interest and excitement amongst fans and viewers.
First Look: Sriram Raghavan's Andhadhun
Posted: September 2, 2018 by moifightclub in bollywood, cinema, film, first look
Tags: Anil Dhawan, Ayushmann Khurana, first look, Radhika Apte, Sriram Raghavan, Tabu, Thriller
When master of the modern Hindi noir, Sriram Raghavan, announced his next project 'Andhadhun', there was a lot of discussion around the name, what it meant, and how it was supposed to be spelt. And of course, what the movie would be about.
The trailer and new poster for the film was released today (film's new release date is now 5th October), and it shows that it is the love story of a blind pianist, who meets a terrific girl and then another woman, and then many things happen to him. Among his inspirations for the film Raghavan counts Fargo, both the film and the series.
The premise is interesting enough, and the trailer makes it even more so. The IMDB synopsis on the film reads: "He sees what he shouldn't. She sees what he couldn't. So the question is, does he see it or not?"
The trailer also revealed that the film stars famous 70s actor Anil Dhawan, which is causing much excitement amongst fans.
Here's the trailer of the film:
Starring: Radhika Apte, Ayushmann Khurana, Tabu, and Anil Dhawan
Producer: Matchbox Pictures, Viacom18 Motion Pictures
Writer & Director: Sriram Raghavan
Editor: Pooja Ladha Surti
Co-writer: Arijit Biswas
Music: Amit Trivedi
Lyrics: Jaideep Sahni
Release: 5th October 2018
Here is Sriram's interview regarding the film on Scroll.
First Look: Shefali Shah and Neeraj Kabi's upcoming Indo-German love story Once Again
Posted: August 31, 2018 by moifightclub in cinema, film, first look
Tags: first look, Neeraj Kabi, Once Again, Shefali Shah
Shefali Shah and Neeraj Kabi's upcoming Indo-German feature love story, Once Again which is slated to release soon.
Witten and Directed by Kanwal Sethi, Once Again is an unusual and mature love story of Tara, a widowed mother who runs a small restaurant and one of her customers, a popular film actor Amar, who she delivers his daily meals. Tara has never seen him – except on the big screen.
Apart from the lead stars, Shefali Shah and Neeraj Kabi, the film features a stellar cast including Rasika Dugal, Bhagwan Tiwari, Bidita Bag and Priyanshu Painyuli.
The music composer, Talvin Singh, who has been at the helm of fusion music, and has played with the likes of Madonna creates an enchanting and melodious soundtrack.
Actor Neeraj Kabi, who was last seen in Netflix show Sacred Games as DCP Parulkar has done diverse roles in films such as Talvar, Byomkesh Bakshi, Ship Of Theseus, Hichki. Excited about playing a romantic hero on celluloid for the first time, Neeraj says, "I have always wanted to perform a love story on celluloid. I am so happy I finally did."
The Indo-German film is produced by Crawling Angel Films, Jar Pictures, Neufilm in collaboration with ZDF/ARTE and is presented by Sanjay Gulati and Neeraj Pandey. ZDF/ARTE are the powerful channels behind films like Lunchbox, Masaan and Qissa.
The film won Facebook Award for the best Work-in-Progress Lab project at the Film Bazaar in Goa.
About the film:
Tara is a widowed mother who runs a small restaurant. One of her customers is popular film actor Amar, she delivers his daily meals. Tara has never seen him – except on the big screen. A chance phone conversation becomes a ritual. They spend hours on the phone, unable to muster the courage to meet. Aware of the reality of an impossible relationship and afraid to transcend the boundaries both have drawn around themselves they live within their safe bubbles. Until one day, when Amar sets out to meet Tara… What follows is a poetic journey of the two lonely hearts in Mumbai, a city of 15 million souls.
About the director:
Kanwal Sethi was born in Amritsar, India. After finishing school, he founded a theatre group and began to stage at various independent theatres. He shifted to Germany and studied Political science and Economics in Dresden. Followed by his own stage productions and parallel to this he started work on his own film projects. His short films and documentaries were screened at various international film festivals as well as the Museum of Modern Art New York. JUNCTION POINT was his debut feature film and premiered at Max ÖphulsPreis and MAMI.
About the Producers:
Neufilm
Since we successfully started producing films 10 years ago, we are constantly confronted with the phenomenon of a separation of art and commerce. Arthouse and mainstream seem to be often incompatible in the industry. The aim of Neufilm is to connect these two poles and make the author film accessible to a broader audience.
Crawling Angel Films
Crawling Angel Films is a film production company based in India that aims to tell the world unique stories through films, which have the quality to capture human emotions through their strong narratives. The dedicated team of Crawling Angel Films is all set out to dissolve the boundaries between the various nations of the globe by getting them well versed with one universal language – the language of Cinema. They have produced award-winning films such as, LAJWANTI (Berlin International Film Festival 2014), ASHWATTHAMA (Busan International Film Festival 2017), MEHSAMPUR and THE SHEPHERDESS AND THE SEVEN SONGS (co-production lab in Film Bazaar and Hong Kong International Film Festival) is currently under the process of shooting.
First Look: Ivan Ayr's Soni (Poster & Trailer)
Posted: August 23, 2018 by moifightclub in Film Festival, first look, News, Trailer
Tags: first look, Hindi, Ivan Ayr, Soni, Venice Film Festival
Ivan Ayr's debut film Soni, which is making its world premiere at the 75th Venice Film Festival under the Orizzonti Competition category just released its first look poster and trailer.
It is the only Indian feature to compete at the festival.
Summary of the film
Soni, a young policewoman in Delhi, and her superintendent, Kalpana, have collectively taken on a growing crisis of violent crimes against women. However, their alliance suffers a major setback when Soni is transferred out for alleged misconduct on duty.
Soni had won the Facebook Award for Best 'Work-In-Progress' Project and Prasad DI Award for the Best Film In 'Film Bazaar Recommends' section at NFDC Film Bazaar 2017.
The film has a running time of 97 minutes and features newcomers Geetika Vidya Ohlyan and Saloni Batra in lead roles. The producers are Kimsi Singh and Kartikeya Narayan Singh, whose previous credits include the 2015 Cannes Un Certain Regard Selection Chauthi Koot.
First Look: Mard Ko Dard Nahi Hota (Trailer)
Posted: August 18, 2018 by moifightclub in cinema, Film Festival, first look
Tags: first look, Midnight Madness, TIFF, trailer, Vasan Bala
The first look of Vasan Bala's upcoming Bollywood-infused action film Mard Ko Dard Nahi Hota (MKDNH) is out. It's teaser cut for the Toronto International Film Festival. Take a look.
MKDNH is the first ever Indian film to be a part of TIFF 18's Midnight Madness. It stars Bhagyashree's son Abhimanyu Dasani and TV star Radhika Madan who is also playing a lead in Vishal Bhardwaj's next. The film is produced by RSVP.
First Look : Devashish Makhija's Ajji (Poster + Trailer)
Posted: September 12, 2017 by moifightclub in cinema, Film Festival, first look, Indie, News, Poster, Trailer
Tags: Ajji, Busan International Film Festival, Devashish Makhija, first look, poster, trailer, Yoodlee Films
Devashish Makhija's new film Ajji will have its world premiere at the Busan International Film Festival's (BIFF) 'New Currents' section. And with the fest line up unveiled, the makers have just released the first look of the film. Check out its poster and the trailer.
Here's the official BIFF program note on the film –
When society fails to provide justice for the rape of nine-year-old Manda, her ailing and arthritic grandmother Ajji tracks down the perpetrator, the son of a local politician, and plots a brutal revenge to serve as a deterrent to all men.
Sushma Deshpande, Sharvani Suryavanshi, Saadiya Siddique, Abhishek Banerjee, Vikas Kumar, Smita Tambe and Sudhir Pandey
The 104 min film has been written by Makhija and Mirat Trivedi. Interestingly, Saregama ventures back into filmmaking with their new brand – Yoodlee Films.
First Look : Anurag Kashyap's 'Mukkabaaz' (Stills + Synopsis)
Posted: September 12, 2017 by moifightclub in cinema, film, Film Festival, first look, Indie, Stills, Story / Plot / Synopsis
Tags: anurag kashyap, first look, Mukkabaaz
With Anurag Kashyap's latest film, Mukkabaaz, having its premiere at the ongoing Toronto International Film Festival, more details are out now.
Here's fest director Cameron Bailey's note on the film, which tells you more about the film
A lower-caste boxer struggles to make his mark on the boxing world, in the highly anticipated film from Anurag Kashyap.
Vital, insightful, and thoroughly cinematic, Anurag Kashyap's The Brawler follows in the tradition of the great boxing films of the past. But the director of Gangs of Wasseypur gives his take on the sweet science a boldly Indian spin. The set-up offers the genre's familiar underdog hero, but this film lands a satisfying punch against the injustices and hypocrisies that keep India's sporting underdogs exactly where they are.
Shravan (Vineet Kumar Singh) is a lower-caste boxer with a tempered edge, struggling to leave his mark and making the case with his fists that he deserves a chance to compete. His career is threatened after he delivers a nasty right hook to the face of Bhagwan — his employer, the local kingpin, and the top boxing promoter in the region. Following this melee, Bhagwan does everything he can to stop Shravan from ascending up the ranks, including preventing him from pursuing the woman he has fallen in love with, Sunaina. Bhagwan will go to any length to punish and humiliate Shravan. But what he doesn't count on is Shravan's tough-mindedness. He's been an underdog all his life and will stop at nothing to go all the way to the Indian National Boxing Championship.
Based on a true story, The Brawler is an enthralling, action-packed tale about corruption and crime in Indian sports. But at the heart of Kashyap's narrative is a smart and complex love story anchored by Zoya Hussain's Sunaina.
Cast + Credits
director – Anurag Kashyap
cast – Vineet Kumar Singh, Zoya Hussain, Ravi Kissan, Jimmy Shergill, Sadhana Singh
Cinematography – Rajeev Ravi Shanker Raman Jay Patel Jayesh Nair
Editing – Aarti Bajaj Ankit Bidyadhar
Executive Producers – Ajay Rai, Kanupriya
Producers – Aanand L. Rai Vikramaditya Motwane Madhu Mantena Anurag Kashyap
Production Companies – Colour Yellow Productions, Phantom Films
Production Designer – Shazia Iqbal
screenplay – Anurag Kashyap, Vineet Kumar Singh, Mukti Singh Srinet, K.D. Satyam, Ranjan Chandel, Prasoon Mishra
sound – Kunal Sharma
Original Score – Rachita Arora
music – Nucleya, Prashant Pillai
First Look : Assamese Filmmaker Rima Das' Film "Village Rockstars"
Posted: September 12, 2017 by moifightclub in cinema, Film Festival, first look, Indie
Tags: Assamese, Rima Das, Village Rockstars
Rima Das' Assamese film, Village Rockstars had its World Premiere at the ongoing Toronto International Film Festival. Interestingly, Rima is also the writer, cinematographer, editor and producer on this one.
Village Rockstars is the only Indian film to be screened in the competition section, DISCOVERY, which features directors from across the world to watch out for. The movie is about a girl, Dhunu, who has grown up in deprivation. She learns to fend for herself in the hostile surroundings while nurturing her dream to own a guitar someday.
The film was selected among the Film Bazaar Recommends at NFDC Film Bazaar 2016. From Film Bazaar the film got picked up by Matthew Poon and was officially selected for the 2017 Marche du Film (Cannes) Work-In-Progress Lab at the 15th Hong Kong-Asia Film Financing Forum and won the WIP Lab project.
Dhunu, a 10 years old girl lives in a remote village in Assam, India amidst raging deprivation. She is a free spirit and her mother, a widower, who struggles daily to bring food to the table and raise her children. However, that does not prevent her from having unrealistic dreams like owning a guitar for her tiny band of village Rockstars boys. Dhunu is a girl who considers herself as capable as boys her age. She and the gangs of boys want to form a rock band. But later the boys slowly stop perusing their dream, whereas Dhunu continues dreaming to own a guitar. Her faith becomes strong when she reads about the law of attraction in a newspaper article. Her unconventional and nonconformist mother raises her with steadfast determination, giving her full freedom of expression and encouraging her to fulfill her dreams. After her father's death, her mother taking all the responsibilities realizes that it is important that a girl should be qualified herself.
But beyond the poverty of her living, attacks nature's fury as her village is flooded and worse than that: the societal restrictions that assail her from the day she reaches puberty. Can Dhunu achieve her simple dream or will she, like hundreds of millions of girls in her situation across the world, have to give up on it!
Bhanita Das, Basanti Das, Kulada Bhattyacharya, Boloram Das,Rinku Das,Bishnu Kalta,Bhaskar Das, Manabendra Das
DIRECTOR- Rima Das
DOP- Rima Das
EDITOR-Rima Das
SCREENPLAY-Rima Das
SOUND-Amrit Pritam
PRODUCER-Rima Das
C0-PRODUCER-Jaya Das
PRODUCTION COMPANY-Flying River Films
INTERNATIONAL SALES-Asian Shadows
LANGUAGE-Assamese
DURATION- 87 MINS, INDIA, DRAMA, HD, COLOUR


text:
Kid 'n Play war ein Hip-Hop- und Comedy-Duo aus New York das seine größte Beliebtheit in den späten 1980er und frühen 1990er Jahren erlebte. Das Duo bestand aus Christopher "Kid" Reid (* 5. April 1964 in der Bronx, New York, NY) und Christopher "Play" Martin (* 10. Juli 1962 in Queens, New York, NY)

Karriere
Neben ihrer erfolgreichen Musikkarriere sollte auch ihre Filmkarriere beachtet werden. Sie produzierten einige Comedy Filme mit Schwerpunkt Musik in den frühen 1990er Jahren und hatten sogar einen eigenen NBC Saturday Morning Cartoon "Kid 'n Play" von 1990 bis 1991. Kid 'n Play drehten gemeinsam vier Filme, wovon drei auf die "House Party" Reihe entfallen. Alle ihre Filme basierten auf Hip-Hop Charakteren oder Themen bezüglich Hip-Hop. Sie erschienen ebenfalls auf den Soundtracks der Filme.

Kid und Play trennten sich Mitte der 1990er Jahre. Kid verfolgte weiterhin die Schauspielerei, war Gast in einigen Sitcoms, die bekannteste davon "Sister, Sister", und moderierte einige Fernsehshows wie "It's Showtime at the Apollo" und "Your Big Break". Play kehrte zum Christentum zurück und arbeitete an christlichen Hip-Hop Projekten.

Diskografie

Studioalben

Singles

Filmografie
 1990–1991: Kid 'N Play
 1990: House Party
 1991: House Party 2
 1992: Class Act
 1994: House Party 3
 2013: House Party: Tonight's the Night

Weblinks

Quellen

Band (New York City)
Hip-Hop-Duo
US-amerikanische Band

redpajama_set_name: RedPajamaWikipedia


text:
When FY-4 encounters the "King of Typhoon": You have been seen through by me. Come on!
At 3:00 p.m. on August 5, "Lekima" arrived in the sea surface 1300 kilometers away from Fuzhou, Fujian Province.
When you are preparing rain gear and food and ready to lie flat on the weekend, you must have known the route of the "King of Typhoon" – "Lekima". "Lekima", the ninth typhoon this year, has presented a fierce and high-profile figure since its appearance on the sea in the east of Philippines at 2 p.m. on August 4, 2019, grabbing the headlines and drawing a lot of attention.
At 3:00 p.m. on August 5, "Lekima" arrived in the sea surface 1300 kilometers away from Fuzhou, Fujian Province. It continued to advance westwards and was highly likely to land China. In response to the challenge of the "King of Typhoon", FY-4A was fully prepared for continuous and intensive observation of "Lekima" to watch its movements.
At 6 p.m. on August 7, "Lekima" continued to approach the sea surface about 1000 km southeast of Taizhou, Zhejiang Province, and the typhoon intensity increased from Level 10 severe tropical storm to Level 16 super typhoon. At the same, the route shifted towards north, and the most likely landing place changed from Taiwan and Fujian to the land or offshore waters of Jiangsu, Zhejiang and Shanghai.
On August 8, "Lekima" developed into the severest typhoon, with the intensity increasing to Level 17. At 5:00 p.m., it was about 650 kilometers from Wenzhou, Zhejiang Province. At 06:00 on August 9, the center of "Lekima" was located on the sea surface about 335 kilometers southeast of Wenling City, Zhejiang Province, and was expected to land on the central and northern coast of Zhejiang Province in the night of August 9 or in the early morning of August 10. It may become the severest typhoon to land in China this year.
Each of the hottest headlines is inseparable from a skillful "behind-the-scenes" pusher. The rising exposure of "Lekima" this time was exactly attributed to the continuous monitoring by FY-4A satellite 36,000 kilometers above the earth.
In order to monitor "Lekima", FY-4A satellite started the intensive observation mode and conducted dynamic monitoring throughout the process, so as to forecast the typhoon route and intensity on a 24-hour basis and provide high-frequency and high-quality observation data for the meteorological department. The advanced geosynchronous radiation imager (AGRI) equipped for the satellite carried out 15-min intensive observation on "Lekima" and provided the cloud map data and temperature and humidity data in and around China; the geosynchronous interferometric infrared sounder (GIIRS) was used to carry out 30-min intensive observation on the typhoon sensitive area obtained by the GRAPES numerical prediction system and provide the vertical profile data of atmospheric temperature and humidity of the typhoon sensitive area; the ground application system can greatly improve the accuracy of typhoon route forecast by conducting data fusion of different observation elements provided by the two high-precision instruments.
Since the launch of the satellite at the end of 2016, FY-4A satellite has become the "mainstay" of China Meteorological Administration when every major meteorological disaster occurred. Since China entered the flood season in March 2019, FY-4A satellite has been on duty 24 hours. With the capability of observing the earth in 15 minutes, observing China in 5 minutes, and observing the area of typhoon or strong convection weather in one minute, FY-4A satellite provides uninterrupted meteorological observation data for China and its surrounding areas, and has made great contribution to preventing and mitigating disasters and ensuring the safety of people's lives and property in China.
In the face of the annual "King of Typhoon", FY-4A satellite has mapped out a strategy and got fully prepared. It therefore can encounter "Lekima" with great confidence: You have been seen through by me. Come on!
Sources of partial materials: National Satellite Meteorological Center, Numerical Weather Prediction Center of CMA
Author: Zhang Liguo
Intelligent "Aerospace" Technology Assists with the Construction of Suzhou Smart City
[Popular Science] A Probe into Satellite Frequency and Orbit Resources


At our company, we believe in making work easier for you. Request an estimate today and we'll come to you! Simply fill out the form below and one of our representatives will get back to you as soon as possible.
Contact us in Santa Paula, California, for an estimate on our used auto parts.
Hours of Operation: Monday–Friday, 8 a.m.–5 p.m. • Saturday, 8 a.m.–2 p.m.


Home dynamix area rugs splash rug multi color within colored idea. Modern rugs vista multi colored area rug wayfair with regard to decorations. Shop safavieh monaco floral ivory multicolored rug x on within multi colored designs. Colorful zest eye catching rug ideas for kids rooms within multi colored idea. Bungalow rose kamberk multicolored area rug reviews wayfair inside multi colored idea.
Green multi colored outdoor rug.
Green multi colored bath rugs. Multi colored rug 9 x 12. Multi colored rugs for living room. Multi colored rug with blue and brick red. Multi colored rugs for nursery. Multi colored rugs uk. Bathroom rugs multi colored. Bungalow rose browndell hand tufted multi colored area rug reviews pertaining to design.


text:
Park Manhattan, at 411-421 Manhattan Avenue between 117th and 118th Avenues, has landed at the top of the City's open house lists.
Since the 38-unit building hit the market in late May, first-time buyers and families have flocked to the five-story condominium conversion in record numbers, according to Charlie Lewis, senior managing director at Warburg Realty Partnership, which is spearheading the sales and marketing of the project.
As a result, the building has delivered 11 signed contracts over a three-month period.
The pre-war building offers studios, one-, two-, and three-bedroom apartments, ranging in price form $169,000 to $497,000.
"The sales momentum at Park Manhattan is unlike anything I've ever seen,"said Lewis.
"The enthusiasm among motivated buyers seems to be contagious, In just three months, we're down to three units. We attribute this to the desirable location, beautiful layouts, and attainable pricing."
The limestone building, which encompasses a full city block, has three private entrances. It's a short walk to Columbia University and steps from Harlem's popular Restaurant Row featuring soul food favorite Melba's, 67 Orange Street, Moca Lounge, Harlem Tavern, Chocolat, Starbucks, and specialty grocer Best Yet Foods.
It is near the B & C trains at 116th Street and the A, B, C, and D trains at 125th Street.
Park Manhattan is a one of the three buildings featured in the Park Collection portfolio.


Make fabric flowers in only a few minutes using scrap fabric and a hot glue gun. We'll show you instructions for how to make two different floral designs that we think will dress up any outfit. So simple, and they look gorgeous!
Handmade fabric flowers are easy to make and so versatile. You can use them to make hair flower clips (I'll show you how), wear as a brooch to brighten up an outfit, or sew them onto a bag. They're a great way to use up scraps of fabric, and best of all they only take a few minutes to make!
On this page we'll show you two methods to make fabric flowers in two different designs; a flat pin-wheel type design, or a more rounded, 3D design.
Now... which type of flower would you like to make?
In this section I'll show you how to make a rounded flower like this. It works best if you use a fabric that's colored on the "wrong" side too, because you'll see both sides of the fabric in the finished flower.
Also, I find that it works well with fabrics that area a little bit stiff or springy, so that the flower holds its shape.
Cut out 9 circles of fabric, about 2 inches (5 cm) in diameter. This will be the size of the finished flower, so you can modify your circle size accordingly.
If you're adding tulle to your flower, then you'll need 9 circles of tulle too.
Cutting out 9 circles can be tedious, so you can save time by folding your fabric over and cutting out several circles at the same time.
You'll also need to cut out two smaller circles from felt. Mine are about 1 inch (2.5 cm) in diameter.
Fold your first fabric circle in half and then in half again to make your first "petal".
Place a blob of hot glue on the folded corner.
Glue the first petal down onto the felt circle.
Glue down three other petals to complete the first layer of your flower.
Now glue down the first petal of the second layer. I like to offset the petal from ones below, but I don't think it really matters.
Glue down the next three petals to complete your second layer. You can "fluff" up the petals at this stage to give your flower more structure.
Now you need to add your final petal to the center of the flower. Fold it as above, and glue it down in the center with a small blob of glue.
Now you'll want to secure a clip onto the back of your flower. Here I'll show you how to attach it to a small hair clip but you can easily attach it to a brooch backing or sew it directly onto an outfit or bag.
Make two small cuts in the second circle of felt and feed your clip through the cuts.
Place a small ring of hot glue on the circle of felt.
Press your clip firmly onto the back of your flower to secure the clip in place.
In this section I'll show you how to make fabric flowers in a flat "pinwheel" style like this one. They look a little bit like daisies.
A good thing about this style is that it's OK to use a fabric that's patterned on one side and blank on the other. Because of the way the petals are folded, the wrong side of the fabric will be hidden.
Cut out 8 circles of fabric, about 2 inches (5 cm) in diameter. The size of these circles will be the size of the finished flower, so you can make them bigger or smaller if you like.
Also, cut out 2 smaller circles of felt, about half the diameter of the others. Mine are about 1 inch (2.5 cm) in diameter. These will go on the back of the flower to give it some structure, and also to attach to a hair clip if you want.
Take on of the big circles, and fold it in half three times. Trim the corners with a pair of scissors so that the folded up fabric looks a bit like an ice-cream.
Do the same thing for all the other big circles, then unfold them. They should look something like this, with a wavy petal-like pattern around the edge.
Take one of the big circles and fold it in half twice, along the same creases that are already in it from folding it a moment ago. This is now one of the petals of your flower. Put a tiny blob of hot glue on the corner of the petal. You don't need much glue.
Press the petal onto the felt circle.
Repeat step 4 with another petal, and glue it down on top of the first petal but offset by 45° (one eighth of a circle) to the right.
Keep adding more petals the same way, gluing each one 45° to the right of the one before, until you've added 7 petals in total. Don't add the last petal just yet . Your flower should look something like this.
Take the last petal and cut out a little chunk like this. Cutting it like this will help us squeeze it in between the other petals.
Put a little blob of glue on the back of the petal, then slide it in so that it goes on top of the seventh petal (12-o-clock position in the photo), and under the first petal (3-o-clock position in the photo), like this.
Glue a button or embellishment into the center of the flower to finish it off. You can also glue an alligator hair clip onto the back if you'd like to wear the flower in your hair.
And a selection of other pinwheel flowers too.
I hope you enjoyed learning how to make fabric flowers! How did yours turn out? If you have questions or comments, or just want to say hi, then please contact me with this handy form .


text:
Category Archives: For your information
Sometimes a Nation needs a moment…
Posted in For your information
Tags: #indigenousX, First Nations, Truth
Stop the Commercial Netting of Bournda Lagoon – Petition
Please Sign – https://www.change.org/en-AU/petitions/katrina-hodgkinson-mp-stop-the-commercial-netting-of-bournda-lagoon#supporters
The NSW Department of Primary Industries and Minister Katrina Hodgkinson have released a proposal that would see commercial netting take place in Bournda Lagoon and Sandy Beach Creek, located inside the Bournda National Park
THIS MUST BE STOPPED!
Currently there is a ban on all types of commercial fishing in both the creek and the lagoon, the proposal would allow for the mesh netting of the system targeting all species of fish using 300m wide nets. Bournda Lagoon and Sandy Beach Creek are located in a National Park, they are vital habitats to many species of Flora and Fauna including more than a dozen threatened species, the park is an important element of the local tourism industry and is the home to a number of sacred Aboriginal sites. For these reasons and the more detailed below this proposal should be rejected in full.
Bournda Lagoon
1. Both Bournda Lagoon and Sandy Beach Creek are located inside the Bournda National Park, a place the NSW Government itself describes as a "Natural Playground". This is no place for a Commercial fishing operations, it is a sanctuary to a large range of Flora and Fauna, protected for all citizens of Australia to enjoy and be managed in a sustainable fashion. More than Ten threatened species call the park home including Koalas, Long-Nosed Potoroos, two threatened species of Frogs and more than 200 varieties of Birds. Currently the Lagoon is only accessible by walking track, any vehicle access that would be created for a commercial operation would be a blight on the landscape and require the destruction of the Lagoon's surrounding environment and habitat of many of the parks fauna.
2. Bournda National Park is home to one of the largest Campgrounds on the Far South Coast of NSW, enjoyed by thousands of locals, visitors and school groups throughout the year. Tourism is a vital aspect of the economy of the Far South Coast and the Commercial fishing of Bournda Lagoon would gut the waterway of the fish many recreational fishers come to seek. It would also greatly impact on other Marine and Bird life that are viewed and enjoyed by all visitors. In the Christmas/Summer period the park is at capacity with tourists who come to relax, bushwalk, swim, fish and canoe. This influx of visitors provides a great boost to the local economy in a sustainable fashion that provides many jobs while protecting our shared natural heritage.
3. The two primary species of fish located in Bournda Lagoon, Southern Black Bream/Yellowfin Bream and the Estuary Perch are both long living native species of fish which are only sustainable when fished by recreational anglers who catch and release sexual mature fish. Both species are capable of living to over 30 years old and do not reach sexual maturity until the age of 5 or more in the Lagoon. A single season of commercial fishing could therefore wipe out the entire population. The proposal by the DPI and the Minister allows for the use of 300m wide nets, in NO part of the Lagoon or the Creek is there an area more than 300m wide, meaning that such a net would indiscriminately capture and kill all marine life. Bournda Lagoon is currently closed to the Ocean and has only briefly opened one time in the past 15 years. It is therefore impossible for the Lagoon to ever naturally restock if current residential breeding sized fish are netted.
4. Aboriginal people of the Dhurga language group of the Yuin tribe lived in the Bournda area. There is a continuous and unbroken connection to the land that has previous been recognised by the NSW State Government. Bournda National Park is home to 26 sacred sites a number of which are located directly adjacent to the Lagoon. These sites are so vital to protect that the NSW Government previously warned that "The coastal and estuarine sites are particularly vulnerable to disturbance by recreational use." Yet now contend that a Commercial operation would have no impact. Further highlighting the absurdity of this proposal.
We the petitioners call on the Minister and the DPI to immediately scrap the proposal to allow for any type of Commercial fishing in Bournda Lagoon and Sandy Beach Creek, any other outcome is simply unacceptable to the community.
Tags: Bournda, Commercial Fishing, environment, NSWPOL, petition
The case of Frustration, freeing Peter Greste
Watching the case of Peter Greste, Mohammed Fahmy and Baher Mohammed is becoming increasingly frustrating as the delays and inaction pile up. What should be most concerning to all is that for a case that receives such high profile attention where are the experts who can detail how these events unfold?
When a plane goes missing news services run commentary from the best aviation experts they can find, when there is a storm approaching Australia's best meteorologists are called in to give their best predictions and forecasts. But when an Australian is imprisoned, kidnapped or missing overseas we get no such expert advice. Discussion shows like ABC's The Drum and QandA ask for the opinion of the unqualified; journalists offer up their best guesses and politicians tell us they are doing their best. But how can we know the best is being done, how can we know if those guesses are right or the opinions wrong if we don't have any expert advice as a benchmark from which to work?
This is not an appeal of my own to seek media attention nor feather my own nest, I want nor enjoy neither. But I am one of two senior advocates at Australia's largest and longest running prisoner support service for people detained abroad. I have managed high profile cases, I have worked on many of such cases in Egypt and have been responsible for the release of unjustly held prisoners from the very prison complex in which Peter and his colleagues are currently held.
This is but my job, yet to those in the media to whom I have offered my opinion I have been dismissed by journalists that judging our conversations knew next to nothing of the judicial process in Egypt nor how the formalities are conducted when an Australian is imprison abroad and shrug cluelessly when I ask about "Conops". And yet it is these very journalists who will report on this case, who will offer up opinions and tell the public what they believe they should know. More worrying yet is how drastically out of their depth many of our politicians are. Asked about the action they are taking, politicians from all sides give the sort of answers that could be provided by any observer of the nightly news. For a country with a record of our citizens imprisoned abroad this is simply inexcusable.
I also feel desperately sorry for the Greste family and the families of Mohammed Fahmy and Baher Mohammed, almost daily we see them conduct themselves with stoic composure, grace and humility in the face of great torment and distress. But the reality is I have seen at least 100 other families go through the same thing, most out of the public spotlight but all sharing one thing in common. A Government and a Press that is hopelessly out of their depth to assist those most in need. Families are often more than wary of offering any public criticism of Government whom despite their inabilities are one of the only sources of information and potential assistance.
So it then falls on we the public and the press as the fourth estate to ensure Government is held to account and pressured into doing all they can for a citizen in need. And even more so for a citizen who has committed no crime and in fact was doing his job in the service of all of us to deliver the very free press we so desire. While it is commendable that so many in the global media have shown solidarity with Mr Greste and freeing the AJ Staff, Posting pics on social media is simply not enough. Twitter is not the voice that will force the release of Mr Greste, but a much more powerful one is held by the global press. Their TV stations, their newspapers, their radio programs. These are the tools that must be used by journalists most committed to see the AJ Staff released. Forget the selfie with the hastag, pick up your microphone, your camera or your pen. Because it is these tools that not only capture the widest audience but place the most pressure on the people in power whom will decide Mr Greste's future.
From pressuring the Australian Government to do more, to speaking to experts so they know what that more looks like, to exposing the horrendous treatment of the press in Egypt. The media must task themselves with this fight for one very important reason… it was precisely this sort of quality journalism and exposure of the truth that landed the AJ Staff and Mr Greste in prison in the first place. To fight this battle the very best weapon to use is the one the Egyptian Government has so clearly targeted in this case.
Tags: FreeAJStaff, Peter Greste
Queue Jumpers, Dead Hookers and Savages
Queue Jumpers, Dead Hookers and Savages; The real faceless men and women of Australian Politics.
"We must come to see that the end we seek is a society at peace with itself, a society that can live with its conscience. And that will be a day not of the white man, not of the black man. That will be the day of man as man. (Yes)"
The healing power in the truth of Dr Martin Luther King Jnr's words was not just in their wisdom, not just in their moral authority but because they were delivered by a man who was "the other" of his time. The Civil rights movement in the United States was largely centred around abolishing public and private acts of discrimination against Black People. The Jim Crow laws of the South were designed to ensure despite the confederacy loss in the Civil War, African Americans while not kept as slaves were to be second class citizens. Dr Martin Luther King Jnr was one of these such citizens. So where then must we ask in modern battles for civil rights are the voices of Asylum Seekers, First Nations peoples and yes, Sex Workers? If we truly believe in the democratic ideal of Nothing About Us Without Us, the idea that no policy should be decided by any representative without the full and direct participation of members the group(s) affected by that policy. Then where are the loud voices in public, in the media and policy circles of the three "other" groups that I mentioned?
The answer is these groups of "others" are deliberately shut out and the air that would be a space for their voices taken by others. As Liz Thompson brilliantly pointed out in regards to speakers at protests against the treatment of Asylum Seekers "Where is the invitation to the delegates, the resisters and those who brought down Woomera and Baxter from within last time, some of whom are pretty easy to find with a phone call to @RISErefugee." The answer, as I believe Liz also suggested, is too many non-"others" are speaking and filling the space that is most desperately needed to be filled by the "others". Would there have been as much impact from Dr King's famous "I Have a Dream" Speech if it had been delivered by anyone but an African American? Of course not.
Even those of us who advocate on behalf of "others" are not always from that group. In fact in the current Asylum Seeker debate virtually nobody is and thus the power of their words is not only not felt, it is never even heard. Our role as advocates should never be to gain attention for ourselves, never raise a dollar for our own need and to always to lift our clients up above us so that they may be seen and they may be heard. The Indigenous warriors of Chiapas Mexico, the Zapatistas of EZLN have a motto – Para todos todo, para nosotros nada! "For everyone, everything. For us, nothing" They are the "others" but as advocates they know that it is everyone they represent that should be the beneficiaries of their struggles. And the name of their struggle? The Other Campaign.
The very purpose of creating this blog was to promote positive messages about Indigenous Australia, to give air to the issues that matter and to refuse the mainstream media and many politicians very real attempts to paint all things First Nations Peoples as bad, lazy and lacking. Yet despite the efforts of many even the ABC continues to ignore the importance of Nothing About Us Without Us. I have repeatedly contacted The Drum and Q and A over their lack of Indigenous representation, especially when discussing issues directly related to Indigenous people… And heaven forbid be allowed to discuss other issues as well. These inquires conducted formally and often by social media are met with a sort of glazed stupidity, as if this was obvious to nobody and who are these Indigenous experts they could be having on their programs anyway?! If journalists and producers of our National Broadcaster do not know the very existence of Indigenous people of excellence then they have no place in those positions. This is the shutting out of "other" voices, whether deliberate or from sheer ignorance the impact is the same. And now it appears the most IndigenousX of all media, Tracker Magazine, will be shut down. Why? Well we the public have been told a number of reasons, but my opinion is that it is because they have dared tell the truth as "others" about "other" issues.
And if there has been a long tradition of abuse against tribal people and those fleeing war and famine the same has been true for those working in the "oldest profession in the world". When was the last time you heard a Sex Worker speak in the mainstream media about the issues effecting them? The answer is almost never and if they do then this group "othered" by our society must hide their identity or change their name. I offer no opinion here on sex work or the sex industry, but when people stand up and speak about what is best for sex workers by calling them "prostitutes" I must question their motive. When they are told they are priviledged to even have a voice if they manage to get one I say this is wrong. And when a sex worker is brutally murdered in our cities streets and the crime goes unreported by the media I say that this group of "others" has been relegated to second class citizens, demonised and criminalised and is it any wonder that the Scarlet Alliance, the national peak sex worker organisation in Australia, has adopted the motto Nothing About Us Without Us.
Just as I have offered no opinion on the Sex Industry I will not offer an opinion in this article on the struggles of Asylum Seekers and First Nations Peoples other than to say the present conscience of our society that is surely unacceptable while these struggles continue will remain our future until voices are given to the Dr King's of these issues. The Dr Kings who are currently behind wire on Manus, who live in the many First Nations of this land and those whose work is Sex. "Others" are not issues, nor are their advocates them. Taking away nothing from their work but Al Gore is not a climate scientist and Sarah Hanson Young is not an Asylum Seeker. They are political advocates who can be either respected or lampooned, but only the true human face of these struggles can show us their humanity when they are given the space and the voice to do so. Whether it is the MSM and Politicians who deliberately shut out these voices or the advocates who unwittingly take away the air that belongs to others, we will be a community not with a scar, but a gaping wound in the very fabric of who we are until these voices are heard.
It is easy to be painted as a Queue Jumper, a Savage or just another Dead Hooker when you are not given a voice, when your face is never seen and your humanity never acknowledged. When will this end….
"How long? Not long, because the arc of the moral universe is long, but it bends toward justice."
My White Ribbon Day Video
Tags: domestic violence, white ribbon day
Open the Prison Gates on Indigenous Incarceration #FODI
Scanning across the streams of ideas and thoughts that came out of the festival of dangerous ideas I was given much to think about, values of my own to reassess and talented speakers with books I will seek to find time to read. But Dangerous? Not really, a lot of it seemed like common sense coming from Intelligent people who just so happen to be ahead of the social curve. Similarly on the issue of the serious over representation of Indigenous people in the prison system much is written by exceptional people, who clearly identify the magnitude of the problem and offer some good long term solutions that are sadly ignored by a large section of the public and government. But what of today, right now, not just in the years to come?
Aboriginal and Torres Strait Islander Peoples make up 2.5% of the population, yet account for 26% of the prison population. For Juveniles the figures are worse, 40% of those under the age of 18 in the criminal justice system are Aboriginal and Torres Strait Islander youth or children. Those children were, according the Governments own figures, 11 times more likely to be found guilt than their non-Indigenous counter parts and 18 times more likely to be in detention. Since the Royal Commission into Aboriginal Deaths in Custody things have only gotten worse and another generation is being lost to the walls and bars (http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129542188). Based on these simple figures alone it is quite clear that Indigenous people are targeted more frequently by law enforcement, are more often found guilty and much more likely to serve a custodial sentence, both children and adults, for the same crimes also committed by non-Indigenous Australians. Yet the public debate still centres on placing the large portion of the responsibility on Indigenous people while mutual responsibility, let alone state culpability, are scoffed at.
On a real world level take Wilcannia NSW, population 604 of which 77% are Aboriginal people, sees arrests per year exceed the total population. That means some in the community are being arrested more than twice a year, in 1993 that figure was 25 times a year per person in town, some 20,000 arrests in one year for the small country town. While that figure has reduced it remains frighteningly high and most of those arrests are for public drunkenness. Imagine if you can every person in Kings Cross on a Saturday night being arrested for being on the street after consuming too much alcohol. It would be a grave over reaction (although an easy way to fill the cells) if ever there was one, but no different to any night of the week around the country in areas where a considerable number of the population is Indigenous. Feeling targeted is not an illusion of the mind but an everyday reality for those who so often treat undiagnosed health conditions, mental and physical, with the cheapest medicine in town.
The social harm the constant imprisonment of individuals for the most minor of crimes is difficult to measure with any accuracy but take this one figure to give you an idea of just how bad things are. An Aboriginal man in Wilcannia has a life expectancy of just 37 years of age (http://tinyurl.com/mxd4dtj). Let me say that again, a life expectancy of 37 years of age. By 25 you are middle aged, by 30 your health is deteriorating and by 37 you are dead. If Wilcannia was a country it would have the lowest life expectancy in the world. Worse than any African country you can name, worse that any nation stricken by civil war or health epidemic. Yet this occurs in Australia, whom the WHO says Australians can expect a life expectancy of 81 years of age, the 4th highest in the world. The divide between Indigenous and non-Indigenous Australians could not be higher, it is an inequality unmatched around the world.
So while I fully endorse long term solutions, I endorse rational and reasonable policy making based on community consultation that work with community assets and not only their negatives and I fully endorse the much needed building of health, education and employment infrastructure to benefit Indigenous people, I also cannot accept that such a problem can be left only to long term solutions. Just as when a major natural disaster or health epidemic hits another nation we do not simply accept long term solutions but rapid action to ease the burden on those suffering right this very minute.
And we can ease that burden right now, we can reduce the number of Aboriginal and Torres Strait Islanders in prison at this very moment and we can ensure that another generation is not lost to the cells. It will also save billions of dollars that could be better redirected to health, education, legal & community organisations and employment.
My dangerous idea is this: – All Indigenous prisoners (Male, female, adult & juvenile) currently serving a custodial sentence for a victim-less non-violent crime should be released immediately. Their records wiped clean and allowed to return home.
I'm often told that Aboriginal people benefit from imprisonment as they can better access health services or recover from addiction. So ask yourself this, you've had a night out for drinks with friends, you have tonsillitis and you are being told the best way to be cured is not attend your local GP where you will recoup a part of the cost with Government backed Medicare, but to go to your local prison, spend a few months there and hey presto your sore throat is cured and so is your coffee habit. Would you accept that scenario? Let alone if both the addiction and the health issue were far more serious! The vast bulk of those inside prisons suffer mental health issues and have at some point in their life suffered abuse, more of which is likely to follow inside.
So why, for victim-less, non-violent crime would you keep these people imprisoned unless it was simply to warehouse a national disgrace you and the nation do not wish to face. How many young Prof. Larissa Behrendts, Cyril Riolis, Jessica Mauboys or Dr Kelvin Kongs are there sitting in prison cells? And are we willing to do what it takes to ensure another generation is not needlessly lost to our obsession with incarcerating a problem our nation created.
Like those presented at the FODI I do not believe this is dangerous, but common sense, perhaps ahead of what is comfortable for most. But it needs to happen now!
Jeffrey Lee – Finalist NT Australian of the Year Awards 2014
Jeffrey Lee MA is a park ranger in Kakadu for over 20 years and the traditional owner of Koongarra; 1,200 hectares of wilderness, also containing rich reserves of uranium. Most of his adult life has spent fighting to have his land protected from uranium mining. After taking his battle to the world heritage committee in Paris and turning down a large fortune for a clean river and healthy land Jeffrey has recently won his battle and his land will now be incorporated into the national park where it will be protected indefinitely.
This morning he has been recognised for his outstanding contribution by being named as one of four Northern Territory finalists in the Australian of the Year Awards 2014.
"You can make money, you can't make this country back"
Congratulations Jeffrey!
Tags: Australian of the Year, Jeffrey Lee, Kakadu
Bring Him Out – Leonard Peltier
Leonard Peltier, an Anishinabe-Lakota Native American, is a federal prisoner serving two consecutive life sentences for the murders of two Federal Bureau of Investigation (FBI) agents in 1975.
His arrest, his trial and his imprisonment have been tainted with political pressure, falsified evidence and witness intimidation. After more than three decades in prison for a crime it has never been proven he committed and with his health now failing it is time he was released and this sorry chapter in American history closed. Nothing will undo the damage to Mr Peltier's life nor fix the centuries of destruction brought upon his people, but only his release can bring about a forward step in the right direction. No prison should ever hold a political prisoner!
http://www.whoisleonardpeltier.info
Tags: Leonard Peltier, Political Prisoner
50 Years On, Martin Luther King Jr
Martin Luther King's speech more than resonates 50 years later, it remains a statement of fact, a call to justice that has yet to be fulfilled.
Tags: mlk
Help save Andrew & Myuran
Andrew and Myuran, two young Australians, face execution in Indonesia. They have admitted trying to traffic drugs to Australia. They have exhausted their appeals. All that can save them is clemency from Indonesia's President, Susilo Bambang Yudhoyono. We ask you to help in respectfully seeking clemency.
Sign our petition, spread the word and see other ways you can help.
Sign here – mercycampaign.org
Tags: death penalty


Salman's Next Production Updates | Salman Khan Latest News Salman's Next Production Updates: Salman Khan joined hands with First Take Entertainments for a film titled Lions of the Sea.
Bollywood Superstar Salman Khan has been busy shooting for back to back films and all his recent outings ended up as massive blockbusters. The actor is currently in Manali shooting for his next film Tubelight in the direction of Kabir Khan. Along with these, the actor has been producing films on his prestigious Salman Khan Films banner. The actor now teamed up with First Take Entertainments for a film which has been titled Lions of the Sea. The movie is based on a true story and is about a voyage from India to Canada.
The incidents that happened during the event even changed the immigration policies of Canada. The film is all set in the backdrop of 1914 and is about the heartbreaking story of the tragic incident that took 376 lives. Salman is quite excited to join hands for the film and veteran actor Irrfan Khan will be seen in a crucial role. More details about the film to be revealed soon.


text:
Arab Land Initiative
Social Tenure Domain Model
About GLTN
GLTN Partners
GLTN Cluster updates
Land Tools
Access to Land and Tenure Security
Land Administration and Information
Land-Based Financing
Land Management and Planning
Land Policy and Legislation
Crosscutting Issues
Country Work
Land at Scale Uganda
Secure Access to Land and Resources
GLTN Publications
8th GLTN Partners Meeting 2020
The First Arab Land Conference
Improving land tenure security in informal settlements of Nairobi: The journey continues
The draft General comment No. 26 (2022) on Land and Economic, Social and Cultural Rights has been published
The Iraqi authorities officially recognize the Housing, Land and Property rights of the Yazidi minority
Validation workshop of Physical Development Plan (PDP) for Kitumba Sub-County in Kabale District, Uganda
Uganda Prime Minister issues customary land certificates to residents of Kitumba Subcounty in Kabale district
GLTN Country Learning Exchange webinar: Taking stock of phase 3 interventions
What is a Land Tool?
A land tool is a practical way to solve a problem in land administration and management. It is a way to put principles, policies and legislation into effect. The term covers a wide range of methods: a simple checklist to use when conducting a survey, software and accompanying protocols, training modules, or a broad set of guidelines and approaches. The emphasis is on practicality; users should be able to take a land tool and apply it or adapt it to their own situation. Land tools may complement each other. For example, one tool may give overall guidance on how collect data on land use, while another may give detailed instructions on how to assess whether the different needs of women and men are taken into account.
What are the features of pro-poor gender responsive land tools?
The Global Land Tool Network (GLTN) develops tools that benefit all, with special attention to the poor, the women and disadvantaged people. Land tools are pro-poor and gender responsive if they have the following features:
Affordable – The overall cost of the tools should be affordable for both the poor (if they are required to pay user and maintenance fees) and the government or other body that manages the tool.
Equitable and gender-responsive – The land tools should address everyone's needs fairly, while paying particular attention to inequalities faced by women in comparison to men.
Pro-poor – The tools should aim to reduce poverty; they should take the situation and needs of poor people into account and give them a voice in decisions.
Sustainable – It should be possible to implement the tool in the future without large-scale external inputs. Where possible, they should be self-financing through fees or taxes.
Systematic, large-scale -The land tools should be usable at a large scale, be it city-wide or across a whole country, and not just have a one-off, localized use. That means they must be flexible enough to deal with a wide range of situations and can be replicated easily at minimal cost.
Governance – The process of tool development and implementation should take into account how decisions are made regarding access to and use of land, how those decisions are implemented, and how conflicting interests in land are reconciled. Key elements of this include decision-making conflict resolution, with an emphasis on the process and outcomes.
Subsidiarity – Land tools must be sensitive to local situations and needs, and applicable at the lowest appropriate level of authority, whether by the community or at the lowest level of local government.
What are the land tools developed by GLTN?
GLTN land tools can be categorized in areas of work and crosscutting issues.
GLTN Tools and Approaches Matrix
A WORLD IN WHICH EVERYONE ENJOYS SECURE LAND RIGHTS
The Global Land Tool Network (GLTN) is an alliance of international partners contributing to poverty alleviation through increased access to land and tenure security for all. We develop, disseminate and implement pro-poor. gender-responsive land tools that contribute to land reform, good land governance, inclusive land administration, sustainable land management, and functional land sector coordination.
Old GLTN Website
Go to the Dashboard
© The Global Land Tool Network - Facilitated by UNHABITAT, 2021.